PHIL Launches Direct-to-Patient 2.0 Platform to Transform Access, Affordability, and Adherence in Pharma

portfolio company news
Written By Megan Prock McGrath

Phil, a leader in patient access solutions for the life sciences industry, today announced the launch of PHIL Direct, its Direct-to-Patient (DTP) 2.0 platform, designed to help pharmaceutical brands meet evolving patient expectations while navigating affordability, compliance, and policy pressures.

Megan Prock McGrath
Previous

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - $40 million in non-dilutive capital drawn from Neumora’s existing facility with K2 HealthVentures
Next

89bio, Inc. Announces Agreement to be Acquired by Roche